Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference

SAN DIEGO, June 15 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona...

FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia

Once-Daily SAMSCA Increases Serum Sodium Levels Through Increase in Free Water Clearance TOKYO and PRINCETON, N.J., May 21 /PRNewswire/ -- Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced today that the U.S. Food and Drug...

Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity

OSAKA, Japan and FLORHAM PARK, N.J., Feb. 17 /PRNewswire/ -- Shionogi & Co, Ltd. today announced that two distinct year-long studies of velneperit, a novel neuropeptide Y (NPY) Y5 receptor antagonist also known as S-2367, each met their primary endpoint of demonstrating a statistically signifi...

TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks

Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer. New data generated by Naofumi Mukaida and colleagues at Kanazawa University, Japan, identified a central role for the soluble factor TNF-alpha in the development of colon cancer in ...

While Some New Agents Will Achieve Strong Sales, the Migraine Drug Market Will Decline $1.3 Billion by 2018 as Generic Erosion Takes Toll on Top-Selling Brands

...t decade and will exert increasing pressure on new products. However, the emergence of Merck's first-in-class calcitonin gene-related peptide receptor antagonist telcagepant as an alternative to triptan therapy will help counteract market losses -- according to the report, telcagepant will garner sales of $1.3 ...

Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment

...FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market... FIRMAGON is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment o...

FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension

...d Therapeutics and its wholly-owned subsidiary, Lung Rx, Inc. Nearly all clinical experience has been on a background of an endothelin receptor antagonist or a phosphodiesterase type 5 inhibitor. Important Safety Information for TYVASO TYVASO is a prostacyclin vasodilator indicated for ...

QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy

...na (TM), QuatRx has three other product candidates in clinical development and a preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor bet...

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement

...g a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at www.tptxinc.com . FORWARD LOOKING STATEMENTS This ...

Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments

... several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline includin...

Antagonist in Medical Technology

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

Company Also Reports Significant Progress in Advancing Second-Generation CCR9 Drug towards Clinic MOUNTAIN VIEW, Calif., June 12 /PRNewswire/ -- ChemoCentryx, Inc., today announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective R...

Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development

Company Also Provides Update on DARA Program's Ongoing Phase 2a Hypertension Study PRINCETON, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP ), an innovator in the discovery and development of novel small molecule therapeutics, today announced...

Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus

-- CPG 52364, Coley's First Orally-Available, Small Molecule Drug Candidate, Enters Phase I Clinical Development -- WELLESLEY, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced that it has dosed its first subject in a Phase...

Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia

- Phase III data published in the American Journal of Nephrology - DEERFIELD, Ill., Sept. 20 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. today announced that its Phase III data on VAPRISOL was published in the September issue of the American Journal of Nephrology. In this study, VAPR...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin(R) candidate PRS-050, a pot...

Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovatio...

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this stu...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on i...

Curis Announces Hedgehog and Wnt Antagonist Data Presentation at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that its data was included in two presentations at the 98th Annual Meeting of the American Association for Canc...

More>>

Antagonist in Medical Products

CoaguChek XS

Features:...ient blood volume application). Automatic control of internal system functions. Reagent is insensitive to heparin, allowing continuous vitamin K antagonist (VKA) therapy management, e.g. during transition from heparin to VKA therapy. Better clinical outcome: testing more frequently means less risks of ...
Company:Roche Diagnostics

Antagonist in Medical Dictionary

Scar

...d repair in the skin and other tissues of the body. Thus, scarring is a natural part of the healing... Scar is a Disney character and the main antagonist in Walt Disney Pictures' popular 1994 animated movie The Lion King. He was voiced by Jeremy Irons in the English version of The Lion King and his ...

Kinins

...he protein precursor, kininogen, ... Under physiological conditions, endogenous kinins are degraded into inactive ... Aprotinin or the kinin antagonist produced no consistent change in renal ... These studies provide evidence that kinins generated in the kidney participate ... Latest researc...

Antagonist in Biological News

Scientists discover new genetic immune disorder in children

...found in a number of other cases. All the children had inherited mutations in IL1RN, a gene that encodes a protein known as interleukin-1 receptor antagonist (IL-1Ra). IL-1Ra binds to the same cell receptors as the inflammatory protein interleukin-1, and acts as a brake on this inflammatory protein. Without...

Liver disease 'shrunk' by blood-pressure drug

...ork carried out in rat and mouse models allowed the researchers to study what was happening inside the liver when losartan, an angiotensin II receptor antagonist drug, was present. Researchers believe that the drug blocks the signalling pathway so that the liver myofibroblasts die, removing the source of sca...

New drug shows promise in treating drug-resistant prostate cancer

...ecific antigen (PSA) levels a marker for tumor growth in men with CRPC. The new, small organic molecule MDV3100 was "designed as a very strong antagonist of the androgen receptor to stop the growth of any prostate cancer that requires the AR for propagation, which includes most forms of prostate cancer,...

New asthma research opposes current drug treatment, says UH prof

...hard A. Bond, professor of pharmacology at the University of Houston College of Pharmacy (UHCOP), has been investigating whether beta-2 adrenoreceptor antagonist drugs (or beta blockers) ultimately might be a safer, more effective strategy for long-term asthma management than the currently used beta-2 adrenorec...

Gene therapy demonstrates benefit in patients with rheumatoid arthritis

...Gene therapy provided the answer. By implanting a gene in the affected joint, he was able to stimulate production of a human interleukin-1 receptor antagonist protein, which serves to block actions of the interleukin-1 protein. "The idea is that by remaining in place, the new gene can continuously block ...

Promising new drug being evaluated as possible treatment option for fragile X syndrome

...wed there were no adverse side effects from the medication. "This is the first study assessing the safety and pharmokinetic metabolism of an mGluR5 antagonist in humans with Fragile X syndrome," said Dr. Elizabeth Berry-Kravis, pediatric neurologist at Rush and principal investigator of the study. "Also, so...

Motor nerve targeting to limb muscles is controlled by ephrin proteins

...resent in the developing limb (ephrin-A). Using chick and mouse embryos as models, the team of scientists now discovered that nerves connecting to the antagonist muscle group, the flexor muscles, are guided by a closely-related protein family, also present in the developing limb (ephrin-B). Together, these stud...

New regulatory mechanism discovered for cell identify and behavior in forming organs

...ry common in developmental biology, Wnt11 (Wingless), has to be inhibited by the modulating protein Sfrp5 (Secreted Frizzled Related Protein), a known antagonist of Wnt. Without this restriction, Wnt signaling runs amok and the frog's foregut, liver and pancreas form improperly from a cascade of disorganized ce...

Circadian clock may be critical for remembering what you learn, Stanford researchers say

...instead of rhythmic GABA, it is just constant GABA output." To test that idea, Ruby and his colleagues gave the circadian-deficient hamsters a GABA antagonist called pentylenetetrazole, or PTZ, which blocks GABA from binding to synapses, thereby allowing the synapses to continue firing and keeping the brain ...

Treating chronic pain, migraine & muscle spasticity through inhibition of neurotransmitter glutamate

...atment of migraine and other conditions." TorreyPines Therapeutics' lead compound, tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter....

Antagonist in Biological Technology

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

Data published in July 7, 2009 Issue of Proceedings of the National Academy of Sciences QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publi...

WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured. The collaboration was initially established in February ...

ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development

Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire/ -- ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth invest...

Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM ) today announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Works...

ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist

Development Candidate Triggers Milestone Payment from GlaxoSmithKline MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally bioavailable small molecule antagonist of the C5a receptor, CCX168, as a candidate for clinical ...

Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist

Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidat...

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

...prove and enable molecules. The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxon...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

...to improve and enable molecules. The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxon...

TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction

...g a number of acute and chronic diseases and disorders such as migraine and chronic pain. The company currently has two ionotropic glutamate receptor antagonist clinical stage product candidates. Further information is available at www.tptxinc.com . This press release contains forward-looking sta...

Antagonist in Biological Products

Calcium Flux Antagonist Chip, 4-Sipper (coated) from Caliper Life Sciences

Description: Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Company:Caliper Life Sciences

Mast Cell Degranulation colorimetric Assay Kit from CHEMICON

Description:...from human mast cells (2,3). A tryptase inhibitor, protamine, is included as a test inhibitor for screening purposes. Protamine is a potent heparin antagonist that competitively binds heparin, an essential stabilizing factor of mast cell tryptase (Hallgren, 2001; Schwartz, 1986). Protamine has been shown to ...
Company:CHEMICON

Antagonist in Biological Dictionary

Tropism

... ... for identifying HIV viral tropism – CCR5, CXCR4, or dual/mixed. ... Tropism & HIV Resources. What is Trofile™ How to Order Trofile™ CCR5 antagonist & Trofile™ ... Other commonly observed tropisms include galvanotropism or electrotropism, ... The term tropism was formerly applied only to...

SCAR

...ark with a scar . ... Scar (The Lion King) This article does not cite any references or sources. ... Scar is a Disney character and the main antagonist in Walt Disney Pictures' ... Scar - Definition of Scar at Dictionary.com a free online ... Unique system to remove scars Recommended by derma...

Proton pump

...p Inhibitor, contact Parker & Waichman, LLP for a free and confidential consultation ... Proton pump inhibitors and histamine 2 receptor antagonist are prescribed for reflux and GERD. ... How do proton pump inhibitors like nexium help to stop liver ... ...